New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
11:33 EDTPHH, PDH, ZUMZ, AUXL, DVHigh option volume stocks: DV ZUMZ PHH AUXL PDH
News For DV;ZUMZ;PHH;AUXL;PDH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
16:06 EDTAUXLBioSpecifics announces positive CHMP opinion for XIAPEX
BioSpecifics Technologies (BSTC) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion for the use of XIAPEX for the treatment of adult men with Peyronie's disease with a palpable plaque and a curvature deformity of at least 30 degrees at the start of therapy. Swedish Orphan Biovitrum AB is the Marketing Authorization Holder for XIAPEX in 28 EU member countries, as well as Norway and Iceland, and holds the exclusive rights from BioSpecifics' strategic partner Auxilium Pharmaceuticals (AUXL) to commercialize XIAPEX for Dupuytren's contracture and Peyronie's disease indications subject to applicable regulatory approvals.
07:04 EDTAUXLXobi's Xiapex receives positive opinion by CHMP
Swedish Orphan Biovitrum AB and partner Auxilium announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xiapex for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. The use of Xiapex in men with Peyronie's disease is supported by positive safety and efficacy outcome data from two double-blind placebo-controlled studies IMPRESS I and II.
December 19, 2014
06:53 EDTDVWhitie House unveils college ratings blueprint, Reuters says
Subscribe for More Information
December 18, 2014
08:01 EDTDVDeVry to acquire Faculdade Ideal , terms not disclosed
DeVry Education Group announced that DeVry Brasil has entered into an agreement to acquire Faculdade Ideal. Located in Belém, Pará in northern Brazil, Faci currently serves approximately 2,500 students and offers undergraduate programs in high-demand career fields such as law, education, accounting, technology and engineering. The transaction is expected to be completed in the third quarter of fiscal 2015. -
December 16, 2014
16:53 EDTAUXLAuxilium updates court findings in Actavis testosterone gel patent suit
Auxilium (AUXL) disclosed in a filing that as previously disclosed, on May 23 , Auxilium Pharmaceuticals, and FCB I LLC, as licensor of Testim, filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis (ACT) for infringement of FCB’s 10 patents listed in the Orange Book as covering Testim testosterone gel. The lawsuit was filed in response to a notice letter, dated April 12, 2012, sent by Actavis Laboratories, regarding its filing with the U.S. Food and Drug Administration of an Abbreviated New Drug Application for a generic 1% testosterone gel product. This letter also stated that the ANDA contained Paragraph IV certifications with respect to the nine patents listed in the Orange Book on that date as covering Testim. The company’s lawsuit filed against Actavis initially involved those nine patents, as well as a 10th patent covering Testim that was issued on May 15, 2012 and is listed in the Orange Book. By the time that the trial commenced in September 2014, the parties had agreed to remove all but one of those patents from the litigation, with the trial focused solely on claim 3 of U.S. Patent # 7,608,607 . The trial commenced in September 2014 and closing arguments occurred in November 2014. On December 16 , the company learned that Judge Linares held that claim 3 of the ‘607 patent is invalid for obviousness. The Judge also found claim 3 invalid for derivation and improper inventorship, but he declined to rule on whether correction of inventorship would be appropriate because it would be futile in light of his ruling on obviousness. Auxilium believes that Actavis is now free to enter the market with its testosterone gel product once it obtains approval from the FDA. At this time, Auxilium is not aware of Actavis having received tentative approval or final approval from the FDA for its testosterone gel product. Auxilium is analyzing the District Court’s opinion and will explore its available options with regard to this matter.
14:19 EDTDVDeVry Brasil to acquire Damásio Educacional
DeVry Education Group announced that DeVry Brasil has signed a definitive agreement to acquire Damásio Educacional. Completion of the transaction is expected to occur February 2015, subject to all regulatory approvals. Damásio is a leader in bar exam test preparation and a high quality provider of undergraduate and graduate law programs. Damásio is expected to generate approximately $50 million in revenue in calendar year 2014. DeVry Group expects Damásio to be modestly accretive to earnings per share in fiscal 2015 and increasing thereafter.
08:58 EDTAUXLEndo a top pick for 2015, says Sterne Agee
Subscribe for More Information
December 11, 2014
17:04 EDTAUXLEndo registration statement relating to Auxilium declared effective by SEC
Subscribe for More Information
December 10, 2014
13:51 EDTPHHT. Rowe Price reports 11.2% passive stake in PHH Corp.
10:10 EDTPHHHigh option volume stocks
Subscribe for More Information
December 8, 2014
07:59 EDTZUMZZumiez weakness a buying opportunity, says Brean Capital
Brean Capital said the weakness in Zumiez is a buying opportunity, as the company's authentic and differentiated merchandise assortment has been instrumental in creating strong brand loyalty, leading to higher productivity levels than its peers. Brean Capital reiterates its Buy rating and $40 price target on Zumiez shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use